Author(s)

Susan Tsai^1*, Kathleen K. Christians¹, Ben George², Paul Ritch², Kiyoko Oshima³, Parag Tolat³, Ashley Krepline¹, Beth A. Erickson⁴, Douglas B. Evans¹

¹Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
²Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
³Division of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴Division of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

The majority of patients with localized pancreatic cancer (PC) who undergo surgery followed by adjuvant therapy will develop metastatic disease, suggesting that surgery alone is not sufficient for cure and micrometastases are present even when are not clinically detected. As such, the delivery of early systemic therapy may be a rational alternative to a surgery-first approach, in an effort to provide oncologic therapies which are commensurate with the disease stage, and improve surgical selection. This review details the rationale for a neoadjuvant approach to localized PC and provides specific recommendations for both pretreatment staging and treatment sequencing for patients with resectable and borderline resectable PC.

Pancreas Cancer, Neoadjuvant Therapy, Review

Tsai, S. , Christians, K. , George, B. , Ritch, P. , Oshima, K. , Tolat, P. , Krepline, A. , Erickson, B. and Evans, D. (2016) Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer. Journal of Cancer Therapy, 7, 24-40. doi: 10.4236/jct.2016.71004.